Allergy Shots Schedule: Frequencies, Protocols, and What Each Visit Involves

During the build-up phase, allergy shots are typically administered one to two times per week. The 2011 AAAAI/ACAAI Practice Parameter defines conventional build-up as one to three injections per week over approximately 8-28 weeks. Once the maintenance dose is reached, injections shift to every 2-4 weeks. Surveys of US allergists show 73% use a 4-week maintenance interval for inhalant allergens. Some practices extend maintenance intervals to every 4-6 weeks for compliant patients after the first year of maintenance. Venom immunotherapy follows a different schedule: maintenance every 4-8 weeks, extendable to every 12 weeks after the first year.

Cluster immunotherapy compresses the build-up phase by administering 2-3 injections of progressively higher doses at each clinic visit, on non-consecutive days. Injections within a visit are spaced approximately 30 minutes apart, with a 30-minute observation period after the final injection. This approach reaches maintenance in approximately 4-8 weeks rather than 3-6 months — roughly 50% fewer total visits during build-up. Per-injection systemic reaction rates are higher with cluster (approximately 3-fold compared to conventional), but per-patient systemic reaction rates are comparable when appropriate patient selection and antihistamine premedication are used. Cluster is suitable for motivated patients with stable, well-controlled asthma who want to reach maintenance faster.

Rush immunotherapy compresses the entire build-up into 1-3 days, with allergen injections administered every 15-60 minutes under continuous medical observation in a closely monitored setting. This approach reaches maintenance in days rather than months and is typically reserved for patients with urgent need for desensitization (such as venom-allergic patients) or highly motivated patients. Rush inhalant immunotherapy requires premedication with antihistamines, leukotriene antagonists, and often oral corticosteroids to reduce the higher systemic reaction risk — rates can approach 20-30% even with premedication. Casale et al. (JACI 2006) showed that omalizumab pretreatment 9 weeks before rush reduced anaphylaxis risk approximately 5-fold. Rush is not appropriate for patients with uncontrolled asthma.

A typical allergy shot visit requires approximately 40-50 minutes of in-clinic time. This includes 10-15 minutes for check-in, pre-injection screening (vital signs, asthma symptom assessment, review of any reactions since last visit), and the injection itself, plus the mandatory 30-minute post-injection observation period. The 30-minute wait is not optional — approximately 85% of systemic reactions occur within 30 minutes of injection, and it is why allergy clinics must have epinephrine and trained staff available. Adding typical commute time, a maintenance allergy shot appointment typically consumes 1.5-2 hours of a patient's day when travel is included.

Missing allergy shots requires dose adjustment based on the duration of the gap, because the desensitized state fades without regular allergen exposure. During build-up: a gap of less than 2 weeks allows normal progression; 2-3 weeks requires repeating the last dose; 3-4 weeks requires reducing by one dose level; 4-5 weeks requires reducing by two dose levels; 90+ days requires restarting from the first dilution vial. During maintenance: less than 5 weeks allows continuation at the same dose; 5-7 weeks requires a 25% dose reduction; 7-11 weeks requires approximately 45% reduction; 3-4+ months requires a full restart. These protocols are empirical consensus — always confirm dose adjustments with your treating allergist.

Yes, the 30-minute post-injection observation period is required after every allergy shot, without exception. This requirement is based on surveillance data showing that approximately 85% of systemic reactions begin within 30 minutes of injection — meaning that the post-injection window captures the vast majority of serious reactions while the patient is still in a monitored clinical setting with epinephrine readily available. A small percentage of reactions (approximately 15%) occur after 30 minutes, which is why patients are also instructed to remain alert for symptoms in the 4-24 hours after each injection. The 30-minute requirement applies to every visit throughout the entire treatment course, including well-established maintenance patients.

Traditionally allergy shots were given in a healthcare setting by a trained professional with immediate access to epinephrine, and the AAAAI/ACAAI Practice Parameter schedules were built around that model because of the small anaphylaxis risk (some insurers, such as UnitedHealthcare as of January 2023, still exclude home-administered SCIT). A personalized compounded serum plus telehealth now makes safe at-home self-administration possible for eligible maintenance patients: Curex pairs a SCIT serum sterile-compounded to USP <797> standards with a board-certified allergist who confirms candidacy, a prescribed epinephrine auto-injector confirmed on hand before the first dose, the first injection and every dose change supervised live over Zoom, and the same gradual escalation clinics use — one weekly shot at home for $129/month. FDA-approved SLIT tablets covering grass, ragweed, and dust mite remain a separate needle-free option taken at home after a supervised first dose.